Craft

Alumis

Stock Price

$12.2

2024-10-29

Market Capitalization

$652.3 M

2024-10-29

Revenue

$24.1 M

FY, 2025

Alumis Summary

Company Summary

Overview
Alumis (formerly known as Esker Therapeutics) is a clinical-stage biopharmaceutical company developing oral therapies. It specializes in the discovery, development, and treatment approaches for autoimmune diseases. The company provides a precision analytics platform with genetic, clinical, and health records data to create medicines.
Type
Public
Status
Active
Founded
2021
HQ
San Francisco, CA, US | view all locations
Website
https://www.alumis.com/
Cybersecurity rating
Sectors

Key People

  • Martin Babler

    Martin Babler, President, Chief Executive Officer, and Chairman of the Board

    • Mark Bradley

      Mark Bradley, Chief Development Officer

      • Sara Klein

        Sara Klein, General Counsel and Secretary

        • John Schroer

          John Schroer, Chief Financial Officer

          LocationsView all

          1 location detected

          • San Francisco, CA HQ

            United States

            280 E Grand Ave.

          Alumis Financials

          Summary Financials

          Revenue (Q1, 2026)
          $1.7M
          Net income (Q1, 2026)
          ($93.1M)
          Cash (FY, 2025)
          $89.7M
          EBIT (Q1, 2026)
          ($98.4M)
          Enterprise value
          $599.5M

          Footer menu